Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation.

Clinical and experimental immunology - 1 Jun 2020

Shamriz O, Simon A J, Lev A, Megged O, Ledder O, Picard E, Joseph L, Molho-Pessach V, Tal Y, Millman P, Slae M, Somech R, Toker O, Berger M

Abstract excerpt

Capping protein regulator and myosin 1 linker 2 (CARMIL2) deficiency is characterized by impaired T cell activation, which is attributed to defective CD28-mediated co-signaling. Herein, we aimed to analyze the effect of exogenous interleukin (IL)-2 on in-vitro T cell activation and proliferation in a family with CARMIL2 deficiency. This study included four children (one male and three females; aged 2·5-10 years...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Inflammatory Bowel Diseases

Share to Interleukin-2

Share to Lymphocyte Activation

Share to Microfilament Proteins

Share to Virus Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 32201938
DOI: 10.1111/cei.13432
PMCID: PMC7232008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation.PMID 32201938Read ↗

Evolution and long-term outcomes of combined immunodeficiency due to CARMIL2 deficiency.Semantic proximity Read ↗

A human immunodeficiency syndrome caused by mutations in CARMIL2.Semantic proximity Read ↗

Human CARMIL2 deficiency underlies a broader immunological and clinical phenotype than CD28 deficiency.Semantic proximity Read ↗

Novel CARMIL2 Mutations in Patients with Variable Clinical Dermatitis, Infections, and Combined Immunodeficiency.Semantic proximity Read ↗

Novel CARMIL2 loss-of-function variants are associated with pediatric inflammatory bowel disease.Semantic proximity Read ↗

A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle TumorsSemantic proximity Read ↗

Both integrated and differential regulation of components of the IL-2/IL-2 receptor system.Semantic proximity Read ↗

Costimulatory connections: CARMIL2 and CD28.Semantic proximity Read ↗

Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity.Semantic proximity Read ↗

The scaffolding function of the RLTPR protein explains its essential role for CD28 co-stimulation in mouse and human T cells.Semantic proximity Read ↗

Human IL-2 receptor β mutations associated with defects in immunity and peripheral toleranceSemantic proximity Read ↗

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.